Cas:54262-75-8 3-(azetidin-1-yl)propan-1-amine manufacturer & supplier

We serve Chemical Name:3-(azetidin-1-yl)propan-1-amine CAS:54262-75-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(azetidin-1-yl)propan-1-amine

Chemical Name:3-(azetidin-1-yl)propan-1-amine
CAS.NO:54262-75-8
Synonyms:1-(3-aminopropyl)azetidine;1-(3-aminopropyl)acetidine;N-(3-aminopropyl)azetidine;1-Azetidinepropanamine
Molecular Formula:C6H14N2
Molecular Weight:114.18900
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:29.26000
Exact Mass:114.11600
LogP:0.67910

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-(3-aminopropyl)azetidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Azetidinepropanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(3-aminopropyl)azetidine Use and application,1-Azetidinepropanamine technical grade,usp/ep/jp grade.


Related News: The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 3-(azetidin-1-yl)propan-1-amine manufacturer Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application. 3-(azetidin-1-yl)propan-1-amine supplier The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 3-(azetidin-1-yl)propan-1-amine vendor At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 3-(azetidin-1-yl)propan-1-amine factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.